The gross profit margin of kechuang board companies exceeds 50%, and the pharmaceutical industry ranks first

China Net Finance Daily, May 29 (Reporter Guo Medicine, Intern, Zhu Zhengxue) The establishment of the Kechuang Board has brought more opportunities for a display to many prominent R&D kechuang board enterprises. According to the iFinD statistics of Flush Huan, as of May 28, 105 companies have been listed on the kechuang Board. The average gross profit margins of these companies in 2017-2019 were 51.77%, 52.63%, and 53.49%, respectively. The trend is that competitiveness continues to increase, and in 2019, more than 100 companies have positive returns on net assets.

Median gross margin exceeds 50%

Gross profit margin is one of the important indicators to measure product competitiveness and profitability. In 2019, the average gross profit margin of 105 listed companies of kechuang board companies was 53.49%, and the median gross profit margin reached 50.32%, which was also an increase from 2018. The gross profit margin of all companies exceeds 10%, and the interest rate of 39 companies is above 60%, accounting for 37.14%.

Among them, Baolan ranked first with a gross profit margin of 96.46%, and Microchip Biotech ranked second with a gross profit margin of 95.81%. In addition, the gross profit margins of 52 companies such as Amethyst Storage, Ruichuang Weina, and Platinum are between 30%-60%. It is worth noting that the 55 companies of Kechuang Board Company Bannan New Pharma, and Pumen Technology have improved their gross profit margin in 2019 compared with 2018, and 33 of them have increased their gross profit margins from 2017 to 2019.

According to Shenwan's first-level classification, since the establishment of the kechuang board, there are 105 listed companies, mainly concentrated in 19 sub-industries, such as non-metallic minerals, pharmaceuticals, and special equipment manufacturing, including pharmaceuticals. Compared with 2018, the average gross profit margin of 12 industries including the technology service industry and food manufacturing industry has increased in 2019.


Four of the top 10 companies in the gross profit margin of Kechuang Board are concentrated in the pharmaceutical manufacturing industry, software, and information technology services, and there are also special equipment manufacturing industries. The top 10 companies with a net return on equity are mainly concentrated in the pharmaceutical manufacturing industry, followed by the software and information technology services industry and the computer, communications, and other electronic equipment manufacturing industries.

Gross margins generally increase

In 2019, among the 19 sub-sectors of the Science and Technology Innovation Board, the pharmaceutical manufacturing industry ranked first in the industry with an average gross profit margin of 72.12%, and it has increased from 2018. Multiple policy support and planning.

Specifically, in addition to Zejing Pharmaceuticals not yet profitable, the average gross profit margin of 13 other companies in the pharmaceutical manufacturing industry can reach 77.66%, and the gross profit margins of 10 companies including Tebao Biological, Huaxi Biological, Haohai Shengke, and Borui Pharmaceutical All are concentrated in more than 70%, of which the core gross profit rate of Weixin is the highest, reaching 95.81%, which is the leading enterprise in the industry.

As shown, the average gross profit margin of the software and information technology services industry will be the second in the industry in 2019 and 2018, and 2019 will increase compared to 2018. In 2017, the "Software and Information Technology Services" Industry Development Plan (2016-2020) released by the Ministry of Industry and Information Technology provided guidance and financial support for the national software and information technology services industry, which is of great significance for promoting the development of the industry.

As of now, there are 19 listed companies in the technology board software and information technology service industries. The average gross profit margin of the industry in 2019 reached 66.04%. The gross profit margins of 11 companies such as Hongruan, Kingsoft Office, and Shanshiwangke all exceeded 60%. Among them, Baolan's gross profit margin was 96.46%.

In addition, the special equipment manufacturing industry has also achieved the average gross profit margin for two consecutive years and ranks in the forefront of the industry. Among the 22 companies listed in this industry, 12 gross profit margins are mainly concentrated in the range of 40%-70%, accounting for 54.55%. The gross profit margin of the other five companies was higher than 70%, accounting for 22.73%. Huafeng Measurement & Control, Xinmai Medical, Ruisong Technology, and other 11 companies have gross margins in 2019 exceeding 2018, and gross profit margins are in the improvement stage.


Guangdong launches action plan to build a high-end equipment manufacturing base

Guangdong is a major manufacturing province with a complete range of industries. However, in the process of industrial transformation and upgrading, "bottleneck" issues such as core technologies remain prominent. Recently, the Guangdong Provincial Department of Industry and Information Technology released the "Guangdong Province Development Plan for Cultivating High-end Equipment Manufacturing Industry" (2021-2025, draft for comments) recommending that it be transformed into manufacturing high-end CNC machine tools, aerospace equipment, satellites, and their applications. Railway transportation equipment, marine engineering equipment, and other important bases for manufacturing high-end equipment nationwide.

The solicitation draft proposes that by 2025, Guangdong will establish multiple national and provincial innovation centers and laboratories to promote breakthroughs in key technologies and key components in key areas. The annual income of the high-end equipment manufacturing industry will increase by more than 6%. Cultivate a group of industry leaders with international influence and independent brand value.

The consultation draft shows that Guangdong has now cultivated a number of equipment manufacturing enterprises and emerging enterprises, and its economic growth has been ranked first in the country for 30 years. But at the same time, the development of the high-end equipment manufacturing industry also faces many challenges: including the key core technology is constrained by people, independent research and development and innovation capabilities are insufficient, the problem of "jam neck" is still prominent; the foundation of heavy equipment is relatively weak, the industrial supporting system is not perfect, and high-end CNC systems, High-reliability electric spindles, cutting tools and other key components depend on the existing supporting equipment, and the large-scale overall machine enterprises are seriously insufficient in their relevance and supporting capacity to small and medium-sized enterprises.

The consultation draft pointed out that Guangdong's high-end equipment manufacturing industry is in a critical period of transforming from element-driven to innovation-driven to digital, networked, and intelligently upgraded. It will pass five key tasks and five key projects. Complete the development goal of maximizing high-end equipment manufacturing in 2021-2025.


Tang Yue, Deputy to the National People's Congress and Chairman of Chutian Technology: Promoting the R&D of Biopharmaceutical Equipment to Meet the "Era of Pharmaceutical Industry 4.0

⊙Reporter Xia Zihang ○ Editor Xu Rui

Just as the National People's Congress deputy, Chu Tian Technology Chairman Tang Yue foresaw a few years ago, where the pharmaceutical industry is fully entering the "pharmaceutical industry 4.0 era." In his view, it is very important to deepen the public health reform of the disease control system, establish a modern disease control management system, and accelerate the development of biopharmaceutical equipment.

Develop pharmaceutical equipment to help prevent and control COVID-19

"The new coronavirus, which has a high infection rate, a long incubation period, and multiple transmission routes, poses a huge challenge to the world's pharmaceutical industry." Tang Yue said.

At this year's two national conferences, Tang Yue put forward "suggestions on accelerating the development of biopharmaceutical equipment and improving local disease prevention and control capabilities." "Biopharmaceuticals are an important part of the national economy and have a closer relationship with people's livelihood. The main popular figure Tang Yue said that at present, the gap between the level of domestic biotechnology and biopharmaceutical core equipment is far from the world's advanced level.

In response to this problem, Tang Yue suggested that the state should introduce supporting policies to encourage the development of biopharmaceutical equipment, focusing on enhancing the emergency production capacity of epidemic prevention and control products; further promoting traditional Chinese medicine, accelerating the research level of Chinese medicine preparation equipment, and promoting Chinese medicine preparation equipment Quickly realize automation, digitalization, and intelligent upgrades; at the same time, encourage school-enterprise cooperation to achieve integrated development of production, education, and research, make full use of talents from universities, research institutes, R&D, technological advantages, and enterprise platforms and market advantages, and actively promote R&D and production, Close cooperation in sales.

The arrival of "the era of pharmaceutical industry 4.0"

A few years ago, Tang Yue said to the Shanghai Securities Journal reporter that in the future, the medical equipment industry will usher in a continuous huge dividend in the world, that is, "pharmaceutical industry 4.0" and the upgrading of pharmaceutical intelligent manufacturing. The direction of development will be obvious after 5 years, and there will be changes in the outline after 10 years. In Tang Yue's view, "Pharmaceutical Industry 4.0" can greatly reduce the hidden dangers of medical safety.

According to reports, pharmaceutical intelligent manufacturing and "Pharmaceutical Industry 4.0" can realize real-time, online, full-range, all-round automatic monitoring of pharmaceutical manufacturing and circulation consumption, and automatically generate data (and cannot be tampered with), automatically read data, Automatically store data to the cloud, zero delays, no dead ends, no blind spots. According to the authorization of the law, regulatory authorities, drug producers, and consumers can consult and retrieve relevant data.

Tang Yue believes that in the future, high-end pharmaceutical equipment, "pharmaceutical industry 4.0" and intelligent manufacturing will be regarded as "rigid demand" for pharmaceutical factories. Based on long-term foresight, Chutian Technology has successfully developed some intelligent pharmaceutical production robots and related production lines using automation and information technology and is transforming into an EPC service provider that builds a "pharmaceutical industry 4.0" smart factory overall solution.

The 2019 annual report shows that Chutian Technology's industrial layout has begun to show its advantages. The traditional advantage of Chutian Technology lies in the liquid pharmaceutical equipment, and its production and sales are at the forefront of the industry; Chutian Huatong, a wholly-owned subsidiary, is a professional research and development of pure steam generator, multi-effect distilled water machine, purified water preparation system, and other products. Manufactured pharmaceutical equipment manufacturing enterprise; Military Pharmaceutical Engineering Design Service of Sichuan Pharmaceutical Design Institute, a wholly-owned subsidiary; Chutian Robot, the holding subsidiary's main products are medical and medical robots; in 2019, Chutian Technology has added an intelligent Chinese medicine machinery product line.

Chutian Technology recently stated on the interactive platform that Sichuan Pharmaceutical Design Institute, a wholly-owned subsidiary of the company, has the design and construction capabilities of the P3 Biosafety Laboratory. During the epidemic prevention and control period, Sichuan Medical Design Institute undertook the design of the high-level biosecurity laboratory (P3) of the Eighth People's Hospital of Guangzhou City, which was highly recognized by hospital experts.

Currently, Chutian Technology is planning a follow-up merger and acquisition of ROMACO. ROMACO is currently the seventh-largest medical equipment company in the world and a senior solid preparation packaging manufacturer. Its products have entered more than 100 countries and regions in the world.


In the Internet age, how does the medical "couple shop" live?

"At the time I was being consulted and my wife was dispensing medicine. When I am the busiest, I will call my cousin to take care of them. Many people in the village come here to see a doctor. "
Speaking of which, Dr. Li's hand in the clinic shook slightly. But the white coat and hair still maintain the rigor of the past, meticulous.

The plaque after the unified reconstruction of the streets has faded, and the outer walls are covered with medical notices and aftertastes of Chinese medicine and disinfection water. All the decorations are the same as the older Dr. Li and his wife: traditional, stubborn, and deadly.

This is a typical small self-employed clinic with a couple of "1 doctor + 1 pharmacist", which is what most medical "couple shops" look like.

"Now that the nurse has resigned, you must clean and disinfect yourself. You can get full every month." Dr. Li took off his glasses, drank strong tea, and took a long breath.

In the half-day of the interview, there was indeed only one guest in the pharmacy in front of us to buy Band-Aid. In addition, most of the time, Dr. Li and his wife Jiang Yaoji are studying how to use the latest online purchase software. As far as the two old doctors are concerned, the learning process is not simple. Finally, they still had to embarrassingly choose to call the service staff of the original pharmaceutical company.

However, once started, the sales staff will follow the software introduction and "enthusiastically" recommend Dr. Li to participate in the clinic upgrade project, and encourage: "Several clinics in your area have joined, and your traditional clinic is outdated. No, It doesn’t matter, we can come over to help you personally."


In response, Dr. Li refused without thinking. He hung up the phone, turned back to "the theory of relativity intelligence," and asked: "I don't understand. In the hospital, our old doctors are also somewhat famous, and the registration fee is a few yuan more expensive. Now that the Internet is coming, should we damn it? "

"Dare you dare to see a doctor on the Internet?"

Before opening his own clinic, Dr. Li was an orthodox medical student of that era and the successor dean of a township hospital.

“After I took office in 2005, the hospital was sold. I couldn’t do anything except seeing a doctor, so I rented a house and opened a clinic. I was in charge of injections, and my wife became a pharmacist. Whenever It is very busy at noon, often eating cold meals or not eating at all. There is no way, once the patient enters the door, we must receive him immediately."

But with this desperate hard work and excellent medical skills, this small clinic of only a few tens of square meters became famous locally in only one year. In 2010, Dr. Li simply bought a facade and expanded the clinic on "his own place".

"He looks fierce. In fact, he has always been an idealist. Those who do not need injections only need oral medicine. In the past SARS, this medicine was very expensive. If you give him more money, he still gets angry. There are six to seven clinics on this street, familiar (people) come often (Dr. Li's clinic), and people who often come from nearby cities..." Li's neighbor quietly asked "Intelligent Relativity".

However, when a company is doing too well, the capital that exudes "fishy smell" will always squeeze into this field and start to compete. In the eyes of capitalists, even life-saving medical treatment is nothing but "business."

Data from the China Health Statistics Yearbook show that between 2010 and 2017, the number of clinics in non-public grassroots medical and health institutions increased from 173,434 to 211,572, an increase of about 22%. The proportion of the total number of institutions rose from 41% to 54%.

Also at that time, Dr. Li and his wife felt that the (clinic) became more and more difficult to do.

Especially in June 2015, "Several Policies and Measures for Promoting the Rapid Development of Social Medical Treatment" (hereinafter referred to as "Measures") was issued. The state proposed to insist on opening medical treatment and implemented "non-prohibited entry" for social capital After the gradual progress, the feeling becomes more obvious.

The "solution" divides qualified social medical institutions into the scope of medical insurance fixed points and implements the same policies as public medical institutions. This solves the medical insurance problem, and also allows the Internet operation model to explode rapidly after the capital officially enters the market, making medical "self-employed" even more difficult to chase.


Good news! New tools for circular DNA sequencing

DNA, also known as deoxyribonucleic acid, we know that biological cells contain a large number of important biological macromolecules, basically one of them is a nucleic acid. DNA is a long polymer composed of repeating nucleotide units and is also a kind of nucleic acid. DNA carries the genetic information necessary for RNA and protein synthesis, and it is an indispensable macromolecule for biological development and normal operation. Before the cell divides, DNA replicates the genetic information of the organism during the replication process. Because it contains complete genetic information, people continue to study it.

At first, when people did not have the concept of DNA, the Swiss biochemist Friedrich Michelle had already separated this substance from the pus of the surgical bandage. But it was not called DNA at the time, but because this microscopic substance was located in the nucleus of the cell, it was called nuclear protein by everyone. It was more than 150 years ago. After this incident, people are just like opening the door to a new world, and a group of scientists is devoted to the study of genes.

After 90 years of exploration, Matthew Mercerson and Franklin Starr confirmed the replication mechanism possessed by DNA in the experiment and inspired the later Creek team to conclude that the genetic code is composed of three The bases are composed in a non-repetitive manner and are called codons. Later, some scientists solved the genetic code formed by these codons in 1961. Therefore, modern gene sequencing projects have also gradually begun.

Current research results divide DNA into three types: single-stranded DNA, closed-loop DNA, and junk DNA. Among them, single-stranded DNA has been studied more, and sequencing methods and technological methods are also more diversified. However, there has been little research on circular DNA, because the lack of effective methods for research and sequencing has hindered progress in this area.

It is understood that circular DNA is very common in the genomes of bacteria and viruses. Circular DNA refers to a closed circular DNA structure located outside the chromosome. Compared with free linear DNA, this circular DNA is not easily degraded by nucleases and is more structurally stable. Moreover, circular DNA is also widely present in various eukaryotes, including humans, with high tissue and disease specificity.

Recently, scientists have discovered a large amount of circular DNA in the nucleus of humans and plants, and also found this circular DNA in cancer cells that are not valued by people. After inferred by experts, it may even be able to reproduce rapidly with cancer cells. There is a certain correlation. Although the traditional view has always been that eukaryotic genomes usually form stable linear chromosomes, new research shows that whether in normal somatic cells or cancer cells, there is a large amount of extrachromosomal circular DNA, and even more, genetic information is stored.

Based on this, scientists have begun to investigate the role of circular DNA in cancer in recent years and overcome their sequencing technology difficulties. Kung Fu takes no pains. According to the physicist organization network, on May 14, a Canadian biologist invented a new tool called CIDER-Seq, which can sequence circular DNA. In fact, they designed a new algorithm based on the knowledge of molecular biology and bioinformatics and used this algorithm to obtain the complete sequence of circular DNA in the experiment. This technique has now been published by researchers on the Internet for other scientists to analyze circular DNA sequences.


This time, the new tool breaks through the original technical difficulties in circular DNA sequencing, or it will provide scientists with more abundant and accurate data for future research. Because the research also shows that many viruses infected with crops have circular DNA, this new technology can also bring benefits to agricultural development. Not only that, but the expanded field of circular DNA research is also expected to promote research on viruses, agriculture, and even cancer.

As we all know, now is the era of rapid development of biology. As a major hot spot in biology, DNA sequencing technology is still relentlessly updated to help scientists dig out more secrets from DNA sequences. As Craig Venter, a well-known expert in human genome research and the chief scientist of Celera Corporation of America said: The meaning of deciphering the genome code is just like in the era when electricity was just discovered, no one can imagine a personal computer, the Internet same. I believe that in the future, the development and progress of sequencing technology can improve people's quality of life to a higher level.


Top scientists have sequenced genes for 1.5 million organisms worldwide. Is this a library or a tombstone?

The fires in Australia, the locust plague in East Africa, and the new crown virus swept the world... After many hardships in 2020, looking back at the opening remarks of Wandering Earth, it seems like a god's prophecy.

"These events are interrelated and closely related to the reduction of the earth's biodiversity." On May 24th, in a video connection across the ocean, Harris Lee, a member of the World Association of Top Scientists (WLA), a recipient of the 2011 Wolf Prize for Agriculture, and professor of evolution and ecology at the University of California, Harris Li Wen tells us.


Professor Li Wen proposed a large scientific project that he named "Earth Biogenome Project" (EBP's Earth Biogenome Project).

This 10-year, costing 5 billion US dollars, sequence, classify and classify the genomes of all 1.5 million known eukaryotes on the planet, will draw a DNA map of all living things on the planet, which is equivalent to Built the Earth Biology Library.

This research may lead to changes in medical treatment methods, solve the problem of global hunger, and create a new "Silicon Valley of Agricultural Science and Biotechnology" in the human backyard. Because of its groundbreaking and importance, EBP is known as the "Moon Landing Plan" of the biological world, and Professor Li Wen has also been rated as a "The Whole World Cataloger" by foreign media.

On May 22, on the 21st International Biodiversity Day, the United Nations announced this year's theme as "Nature, Life for All" (in the natural world). During this period, Professor Li Wen accepted our exclusive interview about the conservation and protection of biodiversity. The future of humanity and the current status of EBP projects and their long-term significance to biodiversity. At the same time, he also shared the current challenges of biology to the popularization of new crowns, and how the EBP project can help new crown pneumonia.

In April 2018, Professor Li Wen was in the Life Science Building at the University of California, Davis. He stood beside the 1998 sculpture by Clarksburg artist Roger Berry, which depicts a DNA sequence.

The unprecedented speed of global species extinction

Biodiversity (English: Biodiversity or Biological Diversity) is a broad concept that describes the degree of diversity in nature.

Although different scholars have different interpretations of biodiversity, it is undeniable that biodiversity resources are an important foundation for us to build civilization. Biological diversity is closely related to the food, therapeutic drugs, and quality of life on which we depend.

According to information published by the United Nations, the needs of at least 40% of the world’s economy and 80% of the world’s poor people come from biological resources. Most of the food, medicines, and raw materials needed for daily production and life are obtained from living things.

Biodiversity maintains ecological balance and maintains environmental stability; biodiversity is also an important object and driving force for human scientific research. In addition, the richer the diversity of life, the greater the chance of discovering new challenges such as drugs, economic development, and adaptation to climate change.

However, today's biodiversity is facing greater trouble than at any time in human history.

In 2019, the United Nations Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services (IPBES) released the "Global Natural State Assessment" report. The report points out that of the 8 million species in the world, 1 million are threatened with extreme extinction due to human activities. The average rate of global extinction is tens to hundreds of times higher than in the past 10 million years.

UN Secretary-General Antonio Guterres said that as we humans invade nature and consume important habitats for animals and plants, more and more species are being put at risk. This also includes our humanity and the future we hope for.


Overcome the core technology of meltblown cloth to achieve multi-spec mass production

Since the outbreak of new pneumonia worldwide, meltblown fabrics have multiplied and become the core material of medical protective masks. In order to ensure that the Boomingshing medical production line of Changhong Technology's subsidiary needs to produce 3 million pieces of mask raw materials every day, and save procurement costs, and make full use of Changhong's powerful mold technology background technology, the group chairman Li Huanchang decided to establish on April 15, 2020. A technical team supporting the research and development of melt-blown fabrics to overcome the precision spinneret technology of melt-blown fabric molds and the production technology of high-temperature injection molding spray glue. The goal is to produce and sell core raw materials.



The first stage, to overcome the core technology of precision spinneret

This task of research and development and production of precision molds has been transferred to its subsidiary Shanghai Changmei Precision Moulds Ltd. On April 15, after receiving the task, Xu Yanping, the general manager of the company, personally selected the technical backbone to form a research and development team. It took only 3 days on April 18 to overcome the precise processing technology of the melter nozzle spinneret and complete the smooth assembly of the 600-hole nozzle module with high efficiency and high quality. Subsequent assembly of various specifications and models, such as 600-type aperture (0.15mm, 0.20mm, 0.25mm, 0.30mm), 1600-type aperture (0.20mm, 0.25mm, 0.30mm).




The second stage, to overcome the high-temperature injection molding production technology

In the coronavirus disease, time is life. On May 2, 2020, the melt-blown fabric production workshop began construction day and night at Changhong Technology's Shenzhen Pingshan Plant, and the equipment installation was completed con May 7 in only 6 days. Xu Yanping, general manager of the company, personally stationed on the front line of the workshop and worked hard with the process engineer to debug the day and night process. On May 8th, he overcame the production technology of high-temperature injection molding of melt-blown cloth. The best combination, 6 production lines to achieve smooth production. Meltblown cloth PFE99 (32L/min, 15pa/cm2), specifications (150, 175, 260), weight (0.22, 0.25, 0.30, 0.40), after testing and certification to achieve industry-leading excellent quality, daily capacity can be reached after capacity release 10 tons +, fully meet the self-production and sales demand of disposable medical masks, N95 mask raw material supply chain.

Changhong Technology is ingenious in fighting against epidemic disease, and we are all committed to the city. We have been working hard to provide high-quality products and services and work tirelessly for the cause of human health!



Shenzhen Changhong Technology Co., Ltd.

May 30, 2020


Announcement on donations to support the fight against the new coronavirus pneumonia epidemic

All members of the company and the board of directors guarantee that the content of information disclosure is true, accurate, and complete without false records, misleading statements, or major omissions.

1. Overview of donations

Shenzhen Changhong Technology Co., Ltd. (hereinafter referred to as "the company") has effectively fulfilled the social responsibilities of listed companies, helping to prevent and control pneumonia caused by new coronaviruses. While doing its own prevention and control work, on February 2, 2020, the company used its own funds to donate 1 million yuan to the epidemic areas in Hubei and other regions through the Shenzhen Red Cross.

According to the "Shenzhen Stock Exchange GEM Stock Listing Rules", "Articles of Association" and other relevant regulations, this donation does not constitute a connected transaction and does not need to be submitted to the company's board of directors and shareholders' general meeting for consideration. It does not constitute a major asset restructuring as prescribed by the China Securities Regulatory Commission's "Management Measures for Major Asset Restructuring of Listed Companies." And does not require approval from other relevant departments.

2. The impact of this donation on the company

The company's external donations are to support the fight against New Coronary Pneumonia and contribute to the prevention and control of New Coronavirus. It meets the requirements of the company's active commitment to social responsibility and is conducive to enhancing the company's social image. This time the external donation funds come from the company's own funds, and will not have a significant impact on the company's current and future operating performance, nor will it have a significant impact on the interests of investors.

Special announcement!

Board of Directors of Shenzhen Changhong Technology Co., Ltd.

February 3, 2020


Voluntary Announcement on New Coronary Pneumonia Related Products

All members of the company and the board of directors guarantee that the content of information disclosure is true, accurate, and complete without false records, misleading statements, or major omissions.

I. Overview

1. Faced with the prevention and control of pneumonia caused by new coronavirus infection, Liyin Precision is acting.

Liyin Precision Medical Products (Shanghai) Co., Ltd. (hereinafter referred to as "Liyin Precision") is a holding subsidiary of Shenzhen Changhong Technology Co., Ltd. (hereinafter referred to as "Changhong Technology" or "Company") and is a research and development company. High-tech enterprises that mainly produce and sell medical device products. Established R&D and innovation centers including central laboratories and test centers, etc., and gradually formed six series of products including specimen collection systems, human-assisted reproductive systems, POCT reagents, sample processing systems, genetic testing reagents and consumables, and laboratory consumables. The mainline of the emerging medical device industry base.

With the rapid spread of the new coronavirus pneumonia epidemic (2019-nCoV), which poses a huge threat to the life and health of the Chinese people, Liyin Precision immediately launched an emergency response mechanism for the epidemic, paying attention to the progress of the disease and organizing The company's R&D, production, quality, logistics, and other departments started construction ahead of schedule to fully prepare for the production of four epidemic-related products. According to the "Notice of the Shanghai Municipal People's Government on Delaying the Resumption of Enterprises and Development of Schools in this Municipality", Liyin Precision actively responded to the spirit and requirements of the national epidemic prevention work and began normal work on February 10, 2020. At that time, the company's internal work arrangements are as follows:

  • For single-use virus sampling tubes, blood collection tubes for nucleic acid detection, biosafety centrifuges, and automatic vacuum blood collection tube sealing machines, priority is given to the production of four types of products related to the recent epidemic.
  • In response to the epidemic situation in Hubei Province, the company will fully cooperate and coordinate various resources to give priority to the production and delivery of orders from customers in Hubei. The company and colleagues in Hubei overcame difficulties together and fought against the epidemic.
  • At present, the company's sales department and marketing department staff have been working online at home, and our staff can be contacted on QQ, WeChat, and telephone.

2. Facing the prevention and control of pneumonia caused by new coronavirus infection, Boomingshing is taking action.

Shenzhen Boomingshing Medical Device Co., Ltd. (hereinafter referred to as "Boomingshing") is a wholly-owned subsidiary of Changhong Technology. It is mainly engaged in the design, development, and production of medical consumables and medical devices, medical tests, and basic equipment and appliances. Processing and sales, mainly for the global market to provide gene products full industry chain consumables, assisted reproductive consumables and reagents, life science laboratory consumables, IVD diagnostic consumables and reagents, special equipment manufacturing products and services.

In the fight against the new pneumonia epidemic of the new coronavirus in 2020, Boomingshing is currently mainly Shenzhen Huada Gene Co., Ltd. (hereinafter referred to as "Huada Gene"), Shenzhen Mindray Biomedical Electronics Co., Ltd. (hereinafter referred to as "Mindray Medical") ") and other customers to provide matching kits and consumable products.

The new coronavirus 2019-nCoV nucleic acid detection kit is a rapid detection kit based on RT-PCR technology and a detection kit based on metagenomic sequencing. Combining the above two detection methods, the 2019-nCoV virus detection can be covered faster and more comprehensively, and the mutations that may occur during the spread of the new coronavirus are monitored. In fact, the kit is the top priority for the diagnosis of new coronavirus. For the detection of the new coronavirus, the most important method at present is to detect whether there is the viral genetic material in humans (sputum, blood, alveolar lavage fluid), so as to confirm whether it is infected by the virus.

As a manufacturer of new coronavirus detection kit supporting products, Boomingshing urgently organized a 65-person team to rush production 24 hours a day and 24 hours after receiving the supply request of Huada Gene on January 30, 2020. The shifting work system, shouldering the mission of the enterprise, satisfies the needs of customers and realizes a daily output of about 28,500 pieces of new coronavirus detection kit supporting products. Boomingshing actively responded to the national epidemic prevention and control spirit and requirements and started construction on February 1, 2020, in advance, giving priority to the research and development and production of the following epidemic-related products.

  • Related consumables using Huada gene DNBSEQ-T7 sequencing system and new coronavirus detection kit;
  • Use the chemiluminescent reaction cup of Mindray Medical Biomedical Biochemical Testing;
  • Blood collection tubes and free DNA tubes for blood testing;
  • 96-well storage plate for gene sequencing.

This product is mainly used for diagnosis, sample collection, and sequencing in epidemic prevention work.

II. Introduce products related to new coronary pneumonia

1. A disposable virus sampling tube

The current new coronavirus is an RNA virus. After the samples are collected, incorrect storage or transportation may cause some nucleic acids to degrade and affect the test results. In addition, unactivated virus samples are likely to cause operator and indirect infection. For the laboratory, the safety level is high; and use existing nucleic acid detection kits, professional specimen collection tools should be used.

The single-use virus sampling tube is used for the collection and transportation of clinical influenza, new coronavirus, avian influenza (such as H7N9), hand-foot-mouth virus, measles, and other virus specimens, as well as mycoplasma, ureaplasma and chlamydia specimens. With the launch of new coronavirus detection reagents and general screening, the demand for single-use virus sampling tubes has increased significantly. In response to the production of products in short supply during the epidemic period, the company has increased its personnel into production during the holidays, and it can be supplied in large quantities one after another.

2. One-time blood collection tube for nucleic acid detection

Labtub® disposable blood collection tubes for nucleic acid detection (referred to as "nucleic acid detection tubes") are specially designed and manufactured for nucleic acid detection, mainly used in blood collection and supply institutions (blood stations, blood centers) and hospitals for venous blood samples for nucleic acid detection Collection, transportation, and storage, as well as pre-treatment of specimen analysis, to meet the clinical nucleic acid amplification test and clinical molecular diagnostic test methods to quickly prepare undiluted plasma specimens.

  • It is produced under pure purification conditions, and the possible pollution is minimized during the production process, effectively reducing the impact of possible carry-over pollution on the experiment.
  • The inner wall of the vacuum blood collection tube is treated with DEPC, the finished product is sterilized by Co60 irradiation, and the sterility guarantee level can reach 10-6, which can completely eliminate the effect of RNase on the experiment.
  • The application of unique additive technology will not affect the activity of the Taq enzyme in the nucleic acid detection experiment, and can effectively eliminate the interference of the hemoglobin in the red blood cell on the nucleic acid detection experiment.

In this new coronary pneumonia, the company's nucleic acid test tube can ensure the accuracy of the blood nucleic acid test results of the new coronavirus. To support epidemic prevention, the company has stocked hundreds of thousands of products.

3. Biosafety centrifuge and automatic vacuum blood collection tube sealing machine

Transmission through the respiratory tract droplets is the main transmission route for 2019-nCoV, and may also be transmitted through contact and aerosol (aerosol). An aerosol is a dispersion system in which solid or liquid particles are suspended in an inverse gas, and the particle diameter is between 0.001 and 100 μm. Medical laboratory and other personnel mainly contact patients' blood, urine, feces, and other samples, which can produce an aerosol. It can effectively eliminate aerosol pollution and avoid the biological contamination of medical personnel and cross-contamination between specimens by aerosol during the uncapping of blood collection tubes.

a. Biosafety centrifuge

Product use: Vacuum blood collection tube (specimen) centrifugal uncap; ordinary specimen centrifugation.

Product advantages: It can prevent aerosol pollution; the speed and centrifuge time of the centrifuge can be set freely, and the centrifugal force can be directly converted and displayed.

b. Automatic vacuum blood collection tube sealing machine

The automatic sealing machine introduced by Liyin Precision for the vacuum storage of blood collection tubes after the analysis of specimens in medical laboratories makes the post-processing of specimens safer, more convenient and more convenient, and is an ideal choice for laboratory safety and quality control.

The product has the following characteristics:

Each sample is sealed independently, so blood samples will not cross-contaminate when stored in the refrigerator. Maintain the originality of the specimen to the greatest extent to ensure the safety of the specimen and the safety of the personnel; discard the previous ordinary cling film cover or manually prevent the sealing method, use automatic machine sealing and stoppering, and the rubber stopper is pressed by the robot. It is suitable for various instrument tube racks without manual sample transfer.

4. Gene storage board

The product has the following characteristics:

Suitable for storage of most polar organic solutions, acidic and alkaline solutions, and other laboratory solutions; suitable for biological fields, such as PCE, RIA, EIA, cell culture, DNA testing, etc.

5. One-time use of vacuum blood collection tube

Scope of application: For the collection, storage, transport, and pretreatment of venous blood samples in clinical laboratories.

III Company performance and risk tips

Since this new coronary pneumonia occurred, sales of the company's kits and other epidemic-related products have increased compared with the same period last year. It is estimated that the subsequent sales revenue will change according to the development of the epidemic. Specific financial data will be disclosed in the 2020 periodic report.

Special announcement!

Board of Directors of Shenzhen Changhong Technology Co., Ltd.

February 6, 2020


Announcement on the completion of the industrial and commercial change registration of wholly-owned subsidiaries

All members of the company and the board of directors guarantee that the content of information disclosure is true, accurate, and complete without false records, misleading statements, or major omissions.

Shenzhen Changhong Technology Co., Ltd. (hereinafter referred to as the "Company") received a notice from the wholly-owned subsidiary Shenzhen Boomingshing Medical Device Co., Ltd. (hereinafter referred to as "Boomingshing"), and actively responded to the call of the national and local governments to take effective actions To support the epidemic prevention of new coronaviruses, the company's business scope will be adjusted accordingly, and "production and management of masks and forehead guns" will be added.

At present, the registration procedures for industrial and commercial change (registration) have been completed and the "Business License" issued by the Shenzhen Municipal Market Supervision Administration has been obtained. The main information is as follows:

Unified Social Credit Code: 91440300552122647A

Company Name: Shenzhen Boomingshing Medical Device Co., Ltd.

Type: Limited liability company (wholly owned by the legal person)

Legal representative: Li Huanchang

Date of establishment: March 11, 2010

Address: Floor 1 to 3, No. 4 Plant, Fuxingda Industrial Park, East Lanzhu Road, Pingshan New District, Shenzhen

Business period: Sustainable operation

Business Scope: Class I (Class I) medical consumables and medical devices, Class II 6841 medical testing and the design and development, production, processing, and sales of basic equipment and appliances, production and operation of masks and forehead guns; digital product accessories, production, processing, and sale of plastic products; import and export of goods, import and export of technology (articles prohibited by laws and administrative regulations; articles restricted by laws and administrative regulations must be licensed before they can operate). Engaged in Class II medical testing and sales of basic equipment; Class II and Class III injection puncture instruments, medical polymer materials and products, medical hygiene materials, and dressings. "

Special announcement!

Board of Directors of Shenzhen Changhong Technology Co., Ltd.

February 19, 2020